Abiopharma

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Register of shareholders, changes and share capital status – exercise and expiration of employee warrants

Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

PDD Holdings Announces First Quarter 2026 Unaudited Financial Results

Nano Dimension Announces Sale of MarkForged, Inc. to Stratasys

Cresco Labs Marks Historic Step Forward with Medical Cannabis Facility DEA Registration

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

Stratasys to Acquire MarkForged, Inc., Expanding Aerospace, Defense, and Industrial Production Capabilities

Net Asset Value(s)